Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131453 · ClinicalTrials.gov registry record · Phase 2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,145
- Enrollment target
NCT03131453: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT03131453 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1,145 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (761% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03131453, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Primary Outcome
Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date
Interventions
- OTHER Matching placebo
- DRUG CNP520 50mg
- DRUG CNP520 15mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 2 |
Why NCT03131453 stopped before completion
NCT03131453 is an interventional study that assigns participants to a tested intervention. Its 1,145 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (761% higher).
The record links to 0 conditions, and to 3 interventions - of which Matching placebo is the first listed.
NCT03131453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03131453 about?
NCT03131453 is a clinical study titled "A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease". The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
What is the current status of trial NCT03131453?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,145 participants. The study started on 2017-08-03. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT03131453?
The interventions under investigation include: Matching placebo (OTHER), CNP520 50mg (DRUG), CNP520 15mg (DRUG).
Who is sponsoring clinical trial NCT03131453?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03131453's enrollment target sits among peer trials
1,145 20th of 2000 higher than 1,981 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI